The Latest Breaking News from Merck

Patients and Researchers Push Back on Cancer Drug Doses That May Be Higher Than Treatment Requires

A KFF Health News investigation finds cancer drugs are often approved at doses higher than needed, leaving patients with avoidable side effects.

Medical Daily · Aug 21

Moderna’s 177% Surge Has Investors Asking What Comes Next

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

MarketBeat · Aug 21

Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches.

International Business Times · Aug 21

A Custom mRNA Therapy Built from Each Patient's Tumor Improved Melanoma Recurrence-Free Survival in a Phase 3 Trial

Merck and Moderna say intismeran autogene plus Keytruda met its primary endpoint in a Phase 3 melanoma trial. What the topline result does and does not show.

Medical Daily · Aug 20

Global Market: China, Hong Kong stocks rebound as healthcare and tech shares rally

China and Hong Kong stocks rebounded on Thursday, led by healthcare and technology shares, after a sharp selloff in the previous session. Fresh share buyback announcements also supported sentiment, while gains in South Korea and Japan helped broader Asian markets recover. Investors remained cautious amid heightened volatility.

The Economic Times · Aug 20

Short Sellers Just Lost $5B on the Wrong Pharma Bet: Cancer Vaccine Sends Stock Soaring 177%

Moderna's shares surged 177% after positive cancer vaccine trial results, causing $5 billion losses for short sellers. This marks a potential shift beyond its COVID-19 vaccine business.

International Business Times UK · Aug 20

Moderna's Personalised Cancer Vaccine Clears Phase 3: How Soon Could Patients Receive It?

Moderna and Merck's personalised cancer vaccine shows positive Phase 3 results, reducing melanoma recurrence risk. Regulatory approval is pending, with potential market availability by 2027.

International Business Times UK · Aug 20

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are…

The Economic Times · Aug 20

Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough

Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win.

Benzinga · Aug 20

Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices closed higher on Wednesday, with the Dow Jones Industrial Average rising 0.22% to 53,463.05, the S&P 500 gaining 0.21% to 7,707.98 and the Nasdaq advancing 0.16% to 26,331.09.

Benzinga · Aug 20